Humanin

Unregulated

Also known as: HN, Mitochondria-derived peptide

Mitochondrial & Longevity

Last reviewed: April 28, 2026

A 21-amino acid peptide encoded within the mitochondrial genome — one of the first mitochondria-derived peptides (MDPs) discovered. Humanin levels decline with age and are associated with longevity in centenarian offspring. Studied for neuroprotection, metabolic health, and cardiovascular protection.

Mechanism of Action

Binds to multiple receptors including gp130, FPRL1, and intracellular IGFBP-3. Activates STAT3 and AMPK signaling pathways. Inhibits neuronal apoptosis, reduces inflammation, improves insulin sensitivity, and protects against ischemic injury. Acts as a stress-response signal from mitochondria to the rest of the cell.

Common Uses

  • Neuroprotection and cognitive support
  • Metabolic health and insulin sensitivity
  • Cardiovascular protection
  • Longevity and anti-aging protocols
  • Alzheimer's disease research

Known Risks

  • Very limited human clinical data
  • Optimal dosing not established
  • Long-term effects unknown
  • Injection site reactions
  • Interactions with other peptides not well characterized

Regulatory Status

Unregulated

Not FDA-approved and not on any compounding list. Available as a research chemical. One of the more scientifically interesting longevity peptides with a growing research base, but human clinical trials are in early stages. Not affected by the 2026 regulatory changes.

Common Protocols

Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.

Subcutaneous injection

Typical Dose

2–4 mg

Frequency

2–3x per week

Cycle Length

4–8 weeks

Emerging compound — dosing is not well-established. Often stacked with MOTS-c for combined mitochondrial support. Best used as part of a broader longevity protocol.

Related Compounds

Research References

This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.